key: cord-0688656-d4dytwdn
authors: Sharma, Prateek; Behl, Tapan; Sharma, Neelam; Singh, Sukhbir; Grewal, Ajmer Singh; Albarrati, Ali; Albratty, Mohammed; Meraya, Abdulkarim M.; Bungau, Simona
title: COVID-19 and Diabetes: Association Intensify Risk Factors for Morbidity and Mortality
date: 2022-05-08
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2022.113089
sha: a5d49bb7e402771547081e481cd97971cdf2bffe
doc_id: 688656
cord_uid: d4dytwdn

Diabetes is a condition that affects a large percentage of the population and it is the leading cause of a wide range of costly complications. Diabetes is linked to a multi-fold increase in mortality and when compared to non-diabetics, the intensity and prevalence of COVID-19 ailment among diabetic individuals are more. Since its discovery in Wuhan, COVID-19 has grown rapidly and shown a wide range of severity. Temperature, lymphopenia, non-productive cough, dyspnoea, and tiredness are recognized as the characteristic of individuals infected with COVID-19 disease. In COVID-19 patients, diabetes and other related comorbidities are substantial predictors of disease and mortality. According to a recent study, SARS-CoV-2 (the virus responsible for covid-19 disease) may also lead to direct pancreatic harm, which could aggravate hyperglycemia and potentially cause the establishment of diabetes in formerly non-diabetic individuals. This bidirectional association of COVID-19 and diabetes load the burden on health care professionals throughout the world. It is recommended that gliptin medications be taken moderately, blood glucose levels must be kept under control, ACE inhibitors should be used in moderation, decrease the number of avoidable hospitalizations, nutritional considerations, and some other prevention measures, such as immunization, are highly recommended. SARS-CoV-2 may cause pleiotropic changes in glucose homeostasis, which could exacerbate the pathophysiology of pre-existing diabetes or result in new disease processes.

The severity of diabetes as a medical problem has risen considerably in the past two decades, making it a worldwide concern [1]. Diabetes afflicted 30 have been documented, with 5,523,538 fatalities. Coronaviridae is a class of encapsulated viruses having a positive RNA genome that is single-stranded [7, 8] . Structure and transmembrane crown-like glycoprotein spikes distinguish this virus from others [9] . The virus utilizes ACE2 (Angiotensin-Converting Enzyme 2) receptors to enter the cell J o u r n a l P r e -p r o o f membranes of the host [10] . When the virus invades the cell of the new host, seizes its genetic machinery and exploits it to produce viral proteins and genetic material. Once replication is completed, the virus escapes the cell by exocytosis, and the stress caused by the virus causes the cell to die [11] . An inflammatory response is triggered when proinflammatory cytokines are activated by the death or necrosis of cells infected with COVID-19. As a consequence of the increased numbers of cytokines in the body, the organism eventually experiences a "cytokine storm." [12] . Multi-organ collapse and hyperinflammation are caused by the cytokine storm [13] . Diabetes screening to discover undiagnosed individuals is crucial with the COVID-19 pandemic [14] . In China, a study (meta-analysis) of COVID-19 patients was performed, indicating a 9.7% prevalence of DM, which is equivalent to China's overall diabetes mellitus incidences [15] . Among the 23,804 participants in the COVID-19 research in the United Kingdom, one-third of the patients had type 2 diabetes (T2D), whereas fewer than 2% had diabetes (Type 1). Diabetes patients have a 2.03 to 3.5 times greater risk of death in the hospital as compared to non-diabetic persons [16] . Covid-19 diabetes patients, compared to non-DM persons, had a greater risk of heart disease, according to a retrospective Chinese study [17] . Covid-19 diabetic patients who had glycated hemoglobin of more than 10% were much more susceptible to COVID-19 than those who had HbA 1c < 6.5 percent, according to population-based cohort research from England [18] .

The virus was discovered to be a new encased RNA β-coronavirus [19] . This virus quickly spread from Wuhan to nearby places in China and it is still spreading around the world [20] . As per the World Health Organization (WHO), illness produced by SARS-CoV-2 is now officially characterized as coronavirus disease . Temperature, lymphopenia, non-productive cough, dyspnoea, and tiredness are recognized as the characteristic of individuals infected with COVID-19 disease. The symptoms of MERS and COVID-19 illness are strikingly similar [21] [22] [23] [24] . The most prevalent means of transmission are aerosols or direct exposure, and infection occurs through the respiratory system [25] [26] .

The variables determining the degree of disease and death remain unclear owing to the uniqueness of sickness. However, it is assumed that those with pre-existing health issues, those who are older, and those who are taken to the hospital late all have a part in the severity of the problem. People having reoccurring health issues like high blood pressure and uncontrolled blood sugar level are considered high-risk factors for contracting the new coronavirus. In addition, it is projected that these individuals would have greater long-term J o u r n a l P r e -p r o o f problems and a higher death rate as a result of this terrible illness. COVID-19 has indirect   impacts on persons who have underlying health problems. For example, while COVID-19   continues to overburden many health services throughout the world, a large proportion of   patients (non-COVID-19) are unable to get the medical treatment they need owing to their pre-existing diseases. Moreover, many individuals have been impacted by the decrease in physical activity as a result of the global lockdowns enforced by most governments, which is particularly crucial for diabetic management. Diabetic patients have an increased chance of sickness, hospitalization, and even death as a result of these repercussions [27] [28] . In the coming years, the economic growth and tourist industry are expected to suffer greatly.

Millions of people have lost their jobs, industries have suffered setbacks, and nearly every aspect of life has been impacted [29] .

This virus belongs to the family Coronaviridae and the genus Beta-coronavirus. Its RNA is single-stranded and positive-sense [30] . The size of the genome of this virus is approximately 29.9 kb, which was recently sequenced and has 78% biological (sequence) homology with SARS-CoV [30] . The SARS-CoV-2 genomic RNA, ORF1a and ORF1b includes 66% of the total genome and is translated into two different proteins namely pp1a and pp1b. A papain-like protease (PLpro), commonly referred to as nsp3 (nonstructural protein 3), and a 3C-like protease (3CLpro), also known as nsp5, are both encoded in the viral genome. Both these proteases cut the polypeptides pp1a and pp1b and generated sixteen non-structural proteins (nsp) [32] [33] . Nsp12 is located in the midsection of the RNAdependent RNA polymerase and is essential for coronavirus replication and transcription. The nsp12 and template-primer RNA pairing was greatly boosted by nsp7 and nsp8 [34, 29] . 

The interval between infection and the development of illness is described as the incubation period. The median incubation duration was 4 days in a group comprising 1099

Chinese patients with lab-confirmed symptomatic COVID-19. Another research with 181 confirmed cases found that the median incubation time was around 5 days and by the 12th day, 97.5% of infected patients had developed symptoms [37] [38] . Depending on the incubation time of SARS-CoV and MERS-CoV, along with scientific data, the US CDC (Centers for Disease Control and Prevention) predicts COVID-19 symptoms to appear 2-14 days after infection. As a consequence, the international norms for monitoring and regulating the mobility of healthy persons have been set at fourteen days.

Most of the early patients of COVID-19 had previously been exposed to a Chinese seafood and animal market in their area, indicating that zoonotic exposure was the primary mechanism of transmission [39] . It has been discovered via viral genome sequencing that SARS-CoV-2 and the bat coronavirus may have shared an ancestral lineage, even though bats aren't sold at this seafood market [40] . Following that, cases were reported in the medical community as well as in people who had no previous contact with animals or who had visited Wuhan, showing the transmission of the disease from person to person [39] . The virus is most often disseminated by direct touch, aerosol, and tiny particles. The virus may transmit to those around when pulmonary droplets from a COVID-19 patient or droplets from a sneeze or cough are swallowed or inhaled. After touching a virus-infested surface or item, people may get infected if they place their hands over their lips, noses, or eyes [41] . Moreover, it has been demonstrated in the laboratory that if a pathogen is breathed or swallowed, it can survive for at least 3 hours in aerosols and can be transferred in confined conditions [41] [42] .

As a consequence, during aerosol-generating therapies such as endotracheal intubation, bronchoscopy, cardiac resuscitation, and so on, the airborne transfer is a concern (Fig. 2) [40, 43] . production of aerosols and droplets by different modes such as sneezing and talking causes the virus to be suspended in the air or settle down depending on particle size, resulting in the development of sickness.

COVID-19 cannot be diagnosed without a microbiologic examination. As there is a limited capacity for screening for COVID-19 in reported incidents, specific criteria for priority patients may be specified by local health agencies. However numerous testing methods have already been created, real-time fluorescence (RT-PCR) is the common model technique for coronavirus detection that identifies viruses in mucus, naso-oropharyngeal samples, and respiratory tract sputum [44] .

There are several plausible pathophysiological explanations for the connection between diabetes and the occurrence of corona virus-19. As the main line of defense against this infection, a weakened body's defensive system is seen in patients with uncontrolled diabetes [45] . Additionally, as demonstrated in COVID-19 sufferers, diabetes is a pro-inflammatory syndrome characterized by an improper and exaggerated cytokine response, where DM patients had significantly greater amounts of interleukin-6 (IL-6), ferritin, and C-reactive protein in their bloodstream compared non-DM individuals [46] . This demonstrates that individuals having unmanaged blood glucose levels are higher vulnerable to cytokine production outbursts, which consequently leads to rapid exacerbation of this devastating disease due to the development of ARDS and shock. Furthermore, preceding research found that COVID-19 subjects with diabetes mellitus had greater D-dimer values than those who did not have diabetes mellitus, probably indicating hemostatic system over-activation [46] .

Hyper-activation of the coagulation cascade in COVID-19 in the context of a preexisting prothrombotic hypercoagulable state exacerbated by the simple presence of DM may result in severe thromboembolic outcomes and eventual mortality [47] [48] .

Diabetes mellitus is associated with decreased expression of angiotensin-converting enzyme 2 (ACE2), an enzyme found in the epithelial cells of alveoli, small intestine, vascular endothelium, and various other human organs. Under normal physiological conditions, ACE2 degrades angiotensin-II and, to a lesser degree, angiotensin-I into smaller peptides known as angiotensin (1-7) and angiotensin (1-9) respectively. Both ACE2 and Ang 1-7 have a beneficial effect in reversing inflammation and oxidative stress. Additionally, ACE2 has been found to protect against transmission of avian influenza A H5N1 [49] . As a consequence, the increased prevalence of ARDS and substantial lung damage associated with this catastrophic condition may be explained by decreased ACE2 expression in DM [50] . ACE inhibitors (ACEi) and angiotensin-receptor blockers have opposing effects that must be considered.

ACEi/ARBs are often used as antihypertensive and reno-protective medicines in people with diabetes. Upregulation of ACE2 is connected to the use of ACEi/ARBs [51] . Ironically, for gaining entry into the recipient pneumocytes, coronavirus targets ACE2; hence enzyme overexpression would assist the corona virus's invasion and subsequent proliferation. As a result, ACE2 is downregulated and fails to defend the lungs after the pathogen utilizes the J o u r n a l P r e -p r o o f enzyme to allow access to the host organism. Hemoglobin's capacity to carry oxygenated blood may be impaired by the non-structural proteins of SARS-CoV-2, which target hemoglobin's β1-chain, according to recent research. Coronavirus may have a stronger tendency for attaching glycated Hb to non-glycated Hb, although this is only a hypothesis [52] .

Diabetes patients with COVID-19 had a less survival rate and a greater mortality rate than non-diabetic patients, according to various studies reported. Dey et al. reported in their first study on 53 old males, who already suffered from diabetes and hypertension. By following a low-glycemic diet and other lifestyle changes, the diabetic patient was successfully controlling his condition. On the 10 th day after getting an infection of COVID-19, serious complications were noticed including diabetic ketoacidosis, hyperglycemic blood level, imbalanced sodium, urea, and potassium level. COVID-19 was detected in the second investigation, which found that a 78-year-old man had been hospitalized previously with the same symptoms. On the ninth day of illness, he got HHS with bilateral pneumonia. He was already taking medicines for diabetes and hypertension. Complications became more drastic for both diabetic patients with the progression over time [53] . Additionally, Maddaloni et al. rate for the diabetic and hyperglycemic patients was found to be approximately triple i.e., 26 .62% corresponding to non-diabetic patient (9.26%). The fatality rate was observed at 24.96% in COVID-19 associated diabetic patients. Moreover, the numbers of adverse events were also more in DM patient than in non-diabetic subjects [55] . Fawares et al. 

Complications in pre-existing diabetic persons, as well as retrospective data from certain research, suggest that COVID-19 is responsible for the genesis of new diabetes. 

People with diabetes often have some degree of chronic inflammation, which may lead to cytokine storms and the death-causing consequences of COVID-19 [13, 68] . Guo et al.

presented the first study of biochemical characteristics of diabetic COVID-19 persons,

indicating that diabetic individuals have a significantly fewer amount of lymphocytes than non-diabetic people, while the number of neutrophils is considerably greater. In further retrospective investigations assessing the clinical parameters of COVID-19 diabetic and nondiabetic patients, elevated NLR, procalcitonin (PCT), and high-sensitivity C response protein (CRP) were also found [46] . Certain inflammation-related indicators were also enhanced in diabetes individuals, with interleukin (IL)-6 being the most elevated among the different markers [69, 70] . Elevated NLR and CRP among COVID-19 individuals along with elevated inflammatory biomarkers were shown to be independent risk factors for disastrous outcomes [70] [71] . Furthermore, preliminary research indicates that tocilizumab which targets IL-6 could enhance COVID-19 therapy. Activation of the monocyte-macrophage cascade is shown by a significant increase in blood protein (ferritin), which is a key component of the cytokine storm. As a result, these findings suggest that patients with diabetes are more likely to trigger an inflammatory storm, resulting in fast COVID-19 precipitation ( fig. 3) J o u r n a l P r e -p r o o f 

Chronic diabetes and uncontrolled blood sugar levels are substantial risk factors in people who have been infected by several viruses [75] [76] [77] . COVID-19 infection and mortality were more common in older individuals with chronic diseases like diabetes, according to various reports published worldwide. In COVID-19 people, there is much less data on glucose homeostasis and the establishment of acute diabetic complications such as ketoacidosis.

COVID-19 diabetics may result in increased stress levels and the production of hormones (glucocorticoids and catecholamines) which elevate the blood sugar content and improper glucose fluctuation [78] . Retrospective research from Wuhan, on the other hand, revealed that almost 10% of COVID-19 diabetics had a minimum single hypoglycemic episode [64] . The activation of pro-inflammatory monocyte and the activation of platelets have been related to reducing blood glucose levels, all of which have been linked to a greater cardiovascular risk 

Insulin sensitivity

J o u r n a l P r e -p r o o f in diabetic patients [79] . Despite this, little is known about the mechanisms through which these individuals' inflammatory and immunological responses function, if hyper or hypoglycemia affects virus pathogenicity, or whether the virus has an effect on insulin release or blood glucose control. Diabetes mellitus is a chronic inflammatory disease that causes lots of new metabolic and vascular issues that might make it difficult to fight infections.

Additional production of AGEs, interleukins, and tissue necrosis factor (pro-inflammatory cytokines), as well as oxidative stress that drives tissue inflammation, are all promoted by hyperglycemia and insulin resistance. This inflammatory process might be the underlying cause of greater susceptibility to infections, as well as worse infection results in diabetic individuals [80] [81] .

There have been several links established between immune system deficits and hyperglycemia, but the clinical relevance of various in vitro modifications is still up in the air [82] . Diabetes that is poorly managed has been connected to a reduced lymphocyte proliferation in response to a variety of sensory stimuli and additionally modified phagocyte responses [83] . Atypical impeded hypersensitivity response and complement proteins stimulation-related abnormalities were documented among diabetics [82, 84] . In vitro experiments have demonstrated that high sugar levels promote influenza virus infection and replication in pulmonary epithelial cells, indicating that high glycemic content in the blood may enhance viral replication in vivo as well [85] . Experiments on animals have indicated that structural lung changes such as increased blood vessel permeability and collapsed pulmonary epithelium are associated with diabetes [86] . Diabetic patients, on the other hand, have a considerable decrease in pulmonary function tests which is linked to elevated glycemic content in plasma [87] .

In diabetics with COVID-19 infection, regular monitoring of blood glucose levels is important, both during hospitalization and quarantine [88] . Maximum mild infections should be handled as normal, except for inhibitors of the sodium-glucose cotransporter-2 which may lead to higher rates of dehydration and diabetic ketoacidosis and necessitate cautious renal function surveillance. Metformin has been associated with lactic acidosis, hence it is recommended that patients with moderate or severe illness discontinue taking it while receiving hospital treatment. Oral hypoglycemic drug (Sulfonylurea) dosage modifications should be made following patient sugar levels, limited food intake, and the danger of hypoglycemia. In addition, discontinuation is highly advocated in hospitalized patients [89] .

Since the usage of dipeptidyl peptidase-4 inhibitors has been associated with a higher risk of upper respiratory tract infections (RTIs), they do not reduce the risk of pneumonia and there is little evidence in favor or opposition regarding their usage [90] . Considering the notion that insulin usage in COVID-19 diabetics is linked to poor consequences, insulin treatment appears to remain a preferred option for hospitalized sick people. All oral anti-diabetic medications should be stopped in hospitalized patients. Depending on the specific therapy strategy, insulin dosages may need to be changed. For quick hyperglycemia treatment, fastacting insulin is employed in individuals who receive basal insulin; blood glucose variation following insulin treatment necessitates vigilant and continuous monitoring [89] . In a retrospective, multicenter trial in China, when compared to improperly managed patients, effective glucose level control (glycemic index 3.9-10.0 mmol/L) has been linked to a lower risk of death [66] . In COVID-19 diabetic patients admitted to the ICU, the most pressing challenges are maintaining proper glycemic control and managing the high insulin requirements. Intravenous steroids, vitamin C, or other drug prescriptions may all lead to increased glucose fluctuation. Depending on the treatment strategy, the physician should choose the most appropriate customized insulin regimen [91] . Hydroxychloroquine has been reported to lower viral load and glycated hemoglobin (HbA1c) in several countries as COVID-19 infection prevention [92] . Hydroxychloroquine, on the other hand, may induce hypoglycemia. Furthermore, hydroxychloroquine in conjunction with metformin has the potential to be hazardous [93] . Despite the positive effects of hydroxychloroquine on glycemic management; long-term treatment in diabetic individuals has been linked to CVS issues and vision problems. Using hydroxychloroquine in individuals with diabetes and COVID-19 may cause severe ventricular arrhythmias, particularly when taken with medications that lengthen the QT interval of ECG [94] .

Type 2 diabetics have a greater risk of morbidity and death from COVID-19 disease. As a consequence, coronavirus disease 2019 causes higher hospital readmission rates and severity of illness in patients with T2D [95] . Furthermore, a patient's prognosis with COVID-19 is worsened by poor glycemic management, which increases the likelihood of ICU treatment due to mechanical resuscitation, trauma, and multi-organ failure [95] . The importance of timely and proper immunization in the primary prevention of disease cannot be underscored.

Pneumococcal pneumonia immunization is recommended regularly and other viral diseases are suggested for people having diabetes [96] . Even though past research has shown J o u r n a l P r e -p r o o f that people with uncontrolled diabetes had reduced antibody responses to several viral vaccinations [97] [98] . Because of recent advancements in vaccine manufacture, patients with diabetes who get vaccinations may now establish a normal immune response. The effectiveness and safety of pneumococcal vaccination have been found to range from 56 percent to 81 percent in numerous case-control studies [99] [100] . In people with diabetes, the side effects of immunization are typically minor. 1568 diabetic patients were vaccinated against pneumonia and influenza at an Indian diabetes clinic. Only joint and muscular discomfort, fever, local rash, and enlarged glands were reported as adverse effects. There were no serious allergic responses recorded. Only 17 out of 2057 DM patients who had pneumococcal vaccines reported slight injection site pain or redness [99] . 

Since diabetes management has been shown to have a detrimental impact on prognosis and increase the chance of infection hence during the COVID-19 epidemic, tight glucose management is essential [109] . Prevention plans that work often involve things like social isolation and thorough cleaning [73] . However, such limits on travel and quarantine should not compromise the availability of effective healthcare services. As a consequence, during the era of this devastating disease, access to healthcare practitioners should be assured [109] . As a result, telehealth services might be a cost-effective way to interact with patients or perhaps identify possible diabetic complications in the early stage, such as indicators of blood glucose dysregulation or infection. Patients should also receive adequate medicine and a glucose assay kit for usage at home. In certain circumstances, access to social care specialists may be required, given the importance of stress management for mental and physical health stability [109] [110] . There is insufficient evidence to recommend discontinuing hypertension, diabetes, J o u r n a l P r e -p r o o f or dyslipidemia drugs; frequent use of anti-diabetic medicines and insulin is recommended [73] . Despite various theories indicating that long-term use of ACE inhibitors and ARBs may enhance the likelihood and severity of infection due to COVID-19 disease, the European Council on Hypertension (ESC Council) strongly advises that patients continue to use their routine hypertension drugs since there is no evidence that they are harmful. The clinical outcomes of ACEi/ARBs in patients with diabetes and hypertension who have COVID-19

were similar to those in the control group, according to a recent study. A healthy lifestyle is required to maintain great glycemic control that includes a balanced diet, frequent cardiovascular activity, and low-weight resistance training [111] [112] .

Diabetes mellitus is a leading cause of a cascade of costly complications, when it strikes young people, it may drive them out of work. Furthermore, COVID-19 illness is a severe respiratory disorder and its virus spread throughout the globe, infecting and killing millions of individuals. Symptoms of COVID-19 include throat infection, temperature, nonproductive cough, lethargy, and diarrhea in all patients. Uncontrolled glucose level is linked to a rise in the intensity of COVID-19 sickness. Pathophysiology, on the other hand, remains unclear. Recognizing the link between COVID-19 and diabetes might lead to therapeutic clinical interventions, however, evidence is scarce on the subject. According to the data, diabetes must always be regarded as a major cause of the severity of COVID-19 symptoms and the ideal function is to lower the exposure to corona sources. Healthcare systems must design programs to reduce diabetes patients' exposure to the risk of disease [113] [114] [115] 64] .

Prompt quarantine, diagnosis, and treatment may all aid in the control of the disease and improve the result. In COVID-19 patients, unmanaged glycemic content and other degenerative diseases are major determinants of illness and death. Diabetes and COVID-19 are two diseases that have a global impact. Approximate 14.5% of COVID-19 patients had diabetes, placing them at greater risk for the severity and lethality of COVID-19. Prevention is the best function, followed by the use of evidence-based therapies. Gliptin medicines should be used in moderation, blood glucose levels must be kept under control, ACE inhibitors should be used in moderation, decrease the number of avoidable hospitalizations, and nutritional considerations and vaccination are some of the recommendations for considering the preventive measure. Therefore, after contracting COVID-19, patients should be monitored for blood glucose levels, alert for ARDS, and given nutritional counseling and referrals as soon as feasible. Diabetes has been demonstrated in tests to impact viral entry into J o u r n a l P r e -p r o o f cells and the inflammatory response. As a result, it's possible that SARS-CoV-2 may cause pleiotropic changes in glucose homeostasis, which could exacerbate the pathophysiology of pre-existing diabetes or result in new disease processes. Future research is critically required to learn more about possible genetic predispositions in different populations, the main pathophysiological processes of the correlation between COVID-19 and diabetes, and its therapeutic care.

There is no conflict of interest in the submission of the manuscript.

Fundings for the publication of this paper are provided by University of Oradea, Oradea, Romania, by an Internal project. 

Origin and evolution of pathogenic coronaviruses

Genetic Recombination, and Pathogenesis of Coronaviruses

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme

Response to Commentary on "The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients

Not so fast: adaptive suppression of innate immunity

COVID-19: consider cytokine storm syndromes and immunosuppression

The clinical characteristics and outcomes of COVID-19 infections in patients with diabetes at a tertiary care center in the UAE

Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19

Associations of type 1 and type 2 diabetes with COVID-19-related mortality

Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study

Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Clinical features of patients infected with 2019 novel coronavirus in

A cluster of cases of severe acute respiratory syndrome in Hong Kong

Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding

Presumed Asymptomatic Carrier Transmission of COVID-19

Clinical characteristics of coronavirus disease 2019 in China

A diabetic patient with 2019-nCoV

infection who recovered and was discharged from hospital

All feet on deck-the role of podiatry during the COVID-19 pandemic: preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes

Coronavirus Disease 2019 (COVID-19) Pandemic and Economic Impact

Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach, BiochimBiophys Acta Mol Basis Dis. 1866 (2020)165878

Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2

Coronaviruses -drug discovery and therapeutic options

The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

China Medical Treatment Expert Group for COVID-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Symptoms at disease onset predict prognosis in COVID-19 disease

First respiratory transmitted food borne outbreak?

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review

Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1

Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations: scientific brief

COVID-19) technical guidance: laboratory testing for 2019-nCoV in humans. World Health Organization

The Effect of Short-Term Hyperglycemia on the Innate Immune System

Diabetes is a risk factor for the progression and prognosis of COVID-19

Type 2 diabetes: an atherothrombotic syndrome

COVID-19 and diabetes: Knowledge in progress

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic

COVID-19: Attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. Cambridge: Cambridge Open Engage

COVID-19 and emergencies in patients with diabetes: two case reports

Clinical features of patients with type 2 diabetes with and without COVID-19: A case control study (COVIDiab I)

New-onset diabetes in COVID-19 and clinical outcomes: A systematic

Diabetes increases the risk of COVID-19 in an altitude dependent manner: An analysis of 1,280,806 Mexican patients

Association Between Diabetes and COVID-19: A Retrospective Observational Study With a Large Sample of 1,880 Cases in Leishenshan Hospital

Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study

Is diabetes mellitus associated with mortality and severity of COVID-19? A metaanalysis

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Features of COVID-19 Patients with Diabetes and Secondary Hyperglycemia

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes

Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control?

COVID-19 and diabetes mellitus: unveiling the interaction of two pandemics

Clinical characteristics and outcomes of patients with severe COVID-19 with diabetes

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19

Patients with diabetes are at higher risk for severe illness from COVID-19

Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed

Rational use of tocilizumab in the treatment of novel coronavirus pneumonia

Spectrum of clinical and radiographic findings in patients with diagnosis of H1N1 and correlation with clinical severity

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS

Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia

Care for diabetes with COVID-19: advice from China

Effect of Hypoglycemia on Inflammatory Responses and the Response to Low-Dose Endotoxemia in Humans

Diabetes and infection: is there a link?--A mini-review

Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms

Immune dysfunction in patients with diabetes mellitus (DM)

Impaired immune responses in diabetes mellitus: analysis of the factors and mechanisms involved. Relevance to the increased susceptibility of diabetic patients to specific infections

High glucose disrupts oligosaccharide recognition function via competitive inhibition: a potential mechanism for immune dysregulation in diabetes mellitus

Glycolytic control of vacuolar-type ATPase activity: a mechanism to regulate influenza viral infection

Alterations of lung structure in experimental diabetes, and diabetes associated with hyperlipidaemia in hamsters

Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study

Encountering COVID-19 as Endocrinologists

Practical recommendations for the management of diabetes in patients with COVID-19

COVID-19 and diabetes: Can DPP4 inhibition play a role?

Early Observation and Mitigation of Challenges in Diabetes Management of COVID-19 Patients in Critical Care Units

Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries

Fatal toxicity of chloroquine or hydroxychloroquine with metformin in mice

Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic

Impact of diabetes mellitus on clinical outcomes in patients affected by COVID-19

Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2020

Use of influenza and pneumococcal vaccines in people with diabetes

Hyporesponsiveness to intradermal administration of hepatitis B vaccine in insulin dependent diabetes mellitus

Suggested use of vaccines in diabetes

Prevention of pneumococcal infection with vaccines: an evolving story

Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

Efficacy and Safety of the mRNA-1273

SARS-CoV-2 Vaccine

Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Impaired anti-SARS-CoV-2 antibody response in non-severe COVID-19 patients with diabetes mellitus: A preliminary report

Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia

Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study

Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™

SAGE_recommendation-AZD1222-2021.1Accessed 15

Diabetes and COVID-19 infection

Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next

Position statement of the ESC Council on Hypertension on ACEinhibitors and angiotensin receptor blockers

Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication

Prevalence of diabetes by race and ethnicity in the United States

Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection

Conceived the idea and wrote the article  Ajmer Singh Grewal and Ali Albarrati: Literature Review  Mohammed Albratty and Abdulkarim M. Meraya: Figure Work  Simona Bungau: Proof Read